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1. Introduction 
After birth, all blood cells are produced in the bone marrow by a process known as 
hematopoiesis. The basic biological process of hematopoiesis is the differentiation of 
hematopoietic stem cells (HSCs) to generate different types of mature blood cells 
(Kawamoto et al., 2010). In an adult, approximately 1012 blood cells are produced daily and 
released into the circulating peripheral blood. As new cells are released, some old cells 
undergo apoptosis in tissues or cleaned by spleen in order to maintain a homeostatic level of 
blood cells. Hematopoiesis is highly regulated through the interaction between 
hematopoietic cells and the bone marrow microenvironment. Many cytokines or growth 
factors and extracellular matrix molecules that are secreted either from stromal cells or from 
hematopoietic cells, as well as nutrients and vitamins, provide a favorable 
microenvironment for hematopoiesis to occur (Metcalf, 2008). Under the influence of 
specific growth factors such as c-KIT ligand and FLT-3 ligand, after rounds of asymmetric 
divisions of hematopoietic stem cells (HSCs), some daughter cells participate in lineage-
commitment differentiation to become either lymphoid or myeloid progenitors. After 
several rounds of proliferation, these progenitor cells undergo terminal differentiation 
becoming mature lymphocytes (B-cells, T-cells and NK-cells) or myeloid cells (granulocytes, 
monocytes, red blood cells, mast cells and platelets). Generation of lymphocytes and 
myeloid cells in bone marrow during hematopoiesis is termed as lymphopoiesis and 
myelopoiesis, respectively. Disruption of these normal physiological processes at the stages 
of HSCs and/or progenitors may initiate leukemogenesis, a neoplastic transformation, and 
result in leukemia. Leukemia is classified as acute or chronic leukemia based on the clinical 
presentation and pathophysiological features. Acute leukemia is classified as acute 
lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) based on the cell 
lineages. Therefore, ALL may be B-cell, T-cell, or NK-cell in origin, while AML may be a 
granulocytic, monocytic, erythroid, or megakaryocytic subtype (Swerdlow et al., 2008; 
Vardiman et al., 2009).  
2. Clinical aspects of acute leukemia  
ALL and AML are the most common leukemias in children and adults, respectively (Siegel 
et al., 2011). Both diseases are characterized by acute onset and rapid accumulation of 
immature leukemic cells (blasts) in the bone marrow and blood (>20% of nucleated cells). 
Leukemic blasts are abnormal because they remain immature and do not function like 
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mature white blood cells. ALL occurs mainly in children with peak prevalence between the 
ages of 2 and 5 years. Approximately 3,200 new ALL cases in childhood are diagnosed in the 
United States each year and two thirds of these cases are the B-cell subtype (Pui et al. 2004). 
Worldwide, ALL occurs approximately 5 cases per 100,000 populations per year. In contrast, 
AML occurs mainly in adults aged 65 years or older with a median age of 60 years 
(Löwenberg et al., 1999; Estey & Döhner, 2006). Approximately 13,400 new AML cases are 
diagnosed in the United States each year. Incidence of AML is about twice that of ALL 
worldwide. The prognosis is much poorer for AML than ALL, especially in elderly patients 
(Estey & Döhner, 2006). 
Both ALL and AML are clonal disorders of hematopoietic stem cells (HSCs) or progenitor 
cells characterized by loss of normal maturation and gain of capacity of uncontrolled 
proliferation (Pui et al. 2004; Estey & Döhner, 2006; Becker et al. 2010). Leukemic blasts 
accumulate in blood and bone marrow and replace normal hematopoietic elements in the 
bone marrow. Furthermore, the blasts can infiltrate other organs and tissues including 
spleen, liver, lymph nodes and even skin. Most patients with acute leukemia present with 
the consequences of bone marrow failure presenting as anemia (decreased red blood cells), 
neutropenia (decreased neutrophils), and thrombocytopenia (decreased platelets). 
Pancytopenia (decreased all types of blood cells) with circulating blasts is the strong 
evidence for the diagnosis of acute leukemia. After diagnosis of a specific subtype of acute 
leukemia with advanced and integrated approaches including clinical information, 
laboratory data, morphology, immunophenotype (flow cytometry or 
immunohistochemistry), and genetic tests (cytogenetic karyotype and molecular genetic 
analysis), an effective chemotherapy regimen must be immediately initiated. The goal of 
treatment is to eliminate the leukemic blasts, preserve and restore normal hematopoiesis, 
and to prevent relapse (Bassan & Hoelzer, 2011; Burnett et al., 2011). To avoid the toxicity of 
chemotherapy, the patients are stratified based on the biological features of leukemia blasts 
and risk factors of the individual patient (host). In addition to clinical factors (age, gender, 
leukocyte count, etc.), specific genetic abnormalities, such as chromosomal translocations 
and/or gene mutations, are the most important factors in determining risk stratification in 
modern treatment of the leukemia patients (Pui et al., 2011). Although the treatment 
regimens are different in ALL and AML, a standard protocol typically consists of three 
phases: a remission-induction phase, an intensification (or consolidation) phase, and a 
continuation (maintenance) phase (Bassan & Hoelzer, 2011; Burnett et al., 2011). The goal of 
remission-induction treatment is to eradicate more than 99% of the initial leukemic cell 
burden and to restore normal hematopoiesis. The intensification treatment is generally 
aimed to eradicate drug-resistant residual leukemic cells including leukemia stem cells 
(Becker & Jordan, 2010). The last phase is maintenance chemotherapy for an additional 2.0-
2.5 years to reduce the risk of relapse. The regimens usually include several drugs that have 
different pharmacological mechanisms of action to have maximal efficacy. In addition to 
routine chemotherapy, allogeneic hematopoietic stem-cell transplantation is the most 
intensive form of treatment for high risk acute leukemia (Gupta et al., 2010). Compared to 
various solid tumors, outcomes are excellent for treatment of acute leukemia, especially in 
young patients. In most large clinical trials, the cure rates are more than 80% and 60% in 
ALL and AML, respectively (Pui et al., 2011). 
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3. Genetic alterations 
Like all other malignancies, acute leukemia is a genetic disease. Specific genetic alterations 
including chromosomal translocation, deletion, addition, and gene mutations (point 
mutation, copy number change) have been identified in all ALL and AML cases. These 
genetic alterations are widely utilized for diagnosis, risk stratification, prediction of 
response to chemotherapeutic reagents, prognosis and detection of minimal residual disease 
(Estey & Döhner, 2006; Swerdlow et al., 2008; Pui et al., 2008).  
3.1 Genetic alterations in ALL 
At the genetic level, ALL is a group of heterogeneous diseases. Standard cytogenetic 
analyses can detect primary chromosomal abnormalities in more than 70% of ALL cases 
(Mrózek et al., 2009). Using higher resolution and/or high throughput molecular methods, 
genetic alterations can be identified in virtually all cases of ALL tested (Mullighan et al., 
2007). These alterations include gene rearrangements, gene copy number changes (deletions 
or duplications) and genomic sequence point mutations. Some of these changes are directly 
linked with leukemogenesis and affect important cellular pathways in cell differentiation, 
cell cycle regulation, tumor suppression, and apoptosis. For instance, PAX5, a B-cell specific 
transcription factor important for B-cell differentiation, was found frequently deleted or 
mutated in B-ALL (Mullighan et al., 2007). Other changes may be merely “passengers” and 
irrelevant to the biological properties and leukemogenesis of ALL.  
The WHO classification of tumors of hematopoietic and lymphoid tissues (Swerdlow et al., 
2008) designates ALL as B- or T-lymphoblastic leukemia/lymphoma based on cell lineages 
and percentage of the blasts in bone marrow. Each lineage group is further categorized as ALL 
with recurrent genetic abnormalities and not otherwise specified (NOS) based on identifiable 
chromosomal abnormalities by routine cytogenetic analysis (Figure 1). B-ALLs with recurrent 
genetic abnormalities include B-ALL with t(9;22)(q34;q11.2); BCR-ABL1, B-ALL with 
t(v;11q23); MLL rearranged, B-ALL with t(12;21)(p13;q22) TEL-AML1(ETV6-RUNX1), B-ALL 
with hyperdiploidy, B-ALL with hypodiploidy, B-ALL with t(5;14)(q31;q32) IL3-IGH, B-ALL 
with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1). Each designation contains the chromosomes 
involved, chromosomal loci, and the genes as well as alternative gene names. This subgroup 
accounts for 60% to 80% of B-ALL cases with distinct biologic and pharmacologic features that 
are important in diagnosis and risk stratification. The remaining B-ALL cases with no 
identifiable chromosomal abnormalities are characterized on the basis of morphologic and 
immunophenotypic features Figure 1A. Fifty to seventy percent of T-ALL patients 
demonstrate abnormal karyotypes. The most common recurrent abnormalities are 
translocations that involve the alpha and delta T-cell receptor loci at 14q11.2, the beta locus at 
7q35, or the gamma locus at 7p14-15, and many partner genes (Pui et al., 2004; Giroux et al., 
2006; Swerdlow et al., 2008). The pathological significance of these abnormalities is not as 
clearly understood as those that are associated with B-ALL.  
3.2 Genetic alterations in AML 
More than 90% of AML cases have at least one known genomic alteration as demonstrated 
by current routine cytogenetic or molecular analysis (Löwenberg et al., 1999) Figure 1B. 
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Using high resolution and high throughput methods, virtually all AML cases are identified 
as having distinct genetic mutations (Estey & Döhner, 2006; Godley et al., 2011).  
A. B. 
 
Fig. 1. Genetic alterations in ALL and AML. Genetic alterations can occur at either 
chromosomal level or DNA sequence level. Although some acute leukemia cases have a 
normal karyotype (A, an ALL patient), there are many mutations detectible at the DNA 
level. Most acute leukemia cases demonstrate specific chromosomal abnormalities that 
defined a distinct subtype of ALL or AML with important diagnostic and prognostic 
applications. The right panel (B) shows a case of acute promyelocytic leukemia (APL) with 
t(15;17)(q22;q12); PML-RARA (with addition at chromosome 7 in this case). APL represents a 
cytogenetically defined AML that can be treated with less toxic all-trans retinoid acid, a 
metabolite of vitamin A, with a favorable prognosis.  
AML is a group of extremely heterogeneous diseases at the genetic level. Based on 
cytogenetic features and cell lineages, the WHO classification of tumors of hematopoietic 
and lymphoid tissues classifies AML into seven cytogenetic types with specific genetic 
abnormalities and nine not otherwise specified (NOS) types based on distinct morphology, 
cytochemistry and immunophenotype (Figure 1B). Furthermore, two provisional subtypes 
have been proposed based on point mutations in NPM1 and CEBPA genes (Swerdlow et al., 
2008, Vardiman et al., 2009; Döhner, 2010). AML with recurrent genetic abnormalities 
include AML with t(8;21)(q22;q22); RUNX1-RUNX1T1, AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11, APL with t(15;17)(q22;q12); PML-RARA (Figure 1B), AML 
with t(9;11)(p22;q23); MLLT3-MLL, AML with t(6;9)(p23;q34); DEK-NUP214, AML with 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1, AML (megakaryoblastic) with 
t(1;22)(p13;q13); RBM15-MKL1. The chromosomes, loci and the genes are indicated in each 
specific designation. Many of these chromosomal translocations result in fusion proteins 
with altered functions of transcription factors critical for normal hematopoiesis and myeloid 
differentiation (Sternberg & Gilliland, 2004). These cytogenetic abnormalities also have 
important diagnostic and therapeutic implications. In contrast, the cases with mutations in 
nucleophosmin (NPM1), CCAAT/enhancer binding protein ǂ (CEBPA), Fms-like tyrosine 
kinase (FLIT3) and KIT genes have been associated with prognosis. More than half of these 
cases with the gene mutations have normal karyotypes (Marcucci et al., 2005; Foran, 2010).  
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New approaches such as whole-genome sequencing, gene expression and microRNA 
profiling, proteomics and genome-wide DNA methylation profiling will not only identify all 
known mutations and epigenetic alterations, but can also potentially identify novel 
mutations and epigenetic lesions in biological pathways at the individual level (Boehm & 
Hahn, 2011). Deciphering the interactions between genetic and epigenetic alterations and 
expression profile will further provide a comprehensive and high resolution blueprint of 
leukemogenesis. That information, in turn, will be applied in clinical management of AML 
patients in the future.  
Over the past few years, high-throughput next generation DNA sequencing (NGS) 
technologies have revolutionized the field of cancer genomics including leukemia (Metzker, 
2010). Recently, Link and colleagues performed whole-genome sequencing on AML 
leukemic cells from a 37 year old woman with suspected cancer susceptibility syndrome 
(Link et al., 2011). The patient developed a therapy-related acute myeloid leukemia (t-AML) 
after chemotherapy for her breast cancer and ovarian cancer. Whole-genome sequencing 
revealed a novel, heterozygous 3-kilobase deletion removing exons 7-9 of TP53 gene in 
germline DNA of patient normal skin cells. The deletion became homozygous in the 
leukemia DNA as a result of uniparental disomic recombination. Additionally, a total of 28 
somatic single-nucleotide variations in coding regions, 8 somatic structural variants, and 12 
somatic copy number alterations were identified in the patient’s leukemia genome. Using a 
similar approach, Welch and colleagues performed whole-genome sequencing on a 39-year-
old woman with a diagnosis of acute promyelocytic leukemia (APL) with unusual genetic 
lesion (Welch et al., 2011). The sequencing identified a novel cryptic insertion of PML gene 
into chromosome 17 that produced a classic pathogenic PML/RARA gene fusion figure 1B. 
This type of genetic event could not have been identified with routine cytogenetic and FISH 
techniques. The results led to a change in therapy using a less toxic targeted reagent, retinoic 
acid, rather than using the high risk procedure of allogeneic bone marrow transplantation.  
These two cases represent excellent examples that whole-genome sequencing in leukemia 
not only detects novel genetic mutations in a cancer genome, but also directly benefits 
patient care. Although next generation sequencing has not been used for routine clinical 
diagnosis due to its high cost and long turnaround time (7 weeks in the latter case), it does 
provide insights for understanding the molecular mechanisms of leukemogenesis at the 
DNA sequence level in individual patients. Most likely, it will be used in clinical diagnosis 
with a “one-size-fits-all” feature in the near future. 
4. Epigenetics 
The completion of the human genome in 2003 held great promise for uncovering the cancer-
causing genetic mutations that would allow for the development of targeted therapies and 
the eradication of cancer. Unfortunately, this has not come to fruition due, in large part, to 
the role of epigenetic modifications in the development of cancer. An individual’s epigenetic 
makeup is much more complex than their genetic makeup. Human DNA sequence in all 
somatic tissue cells (except lymphocytes) is identical in a given individual. However, 
epigenetics presents in a developmental and tissue-specific manor. Epigenetic modifications 
are largely responsible for the differences in all somatic tissue cells such as brain, liver, skin 
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cells, hair cells and the cells that make up the human eye. As a matter of fact, epigenetic 
modifications are responsible for regulating the expression of genes that establish each of 
the tissue types in the body. 
Epigenetics is defined as the change of gene expression caused other than DNA sequence 
change (Bird, 1980; Robertson & Jones, 2000). There are 3 key epigenetic players which work 
in concert to control/alter gene expression. These include DNA methylation, histone 
modifications and non-coding RNAs inference (Figure 2). DNA cytosine methylation occurs 
at the 5th position of cytosine in CpG dinucleotide. Methyl binding proteins are recruited to 
methylated DNA regions and can block transcription factors in the promoter of a gene. The 
inaccessibility of transcription factors to the DNA results in a silenced gene. There are also 
numerous histone modifications such as acetylation, methylation, phosphorylation, 
ubiquitylation and sumoylation which can be present alone or in combination and each has 
an impact on chromatin structure. For example, some histone modifications (histone code) 
are associated with open chromatin (euchromatin) and some are associated with condensed 
chromatin (heterochromatin). If the chromatin is open, genes are accessible and can be 
transcribed. Alternately if the chromatin is closed, the genes are inaccessible to transcription  
DNA 
methylation
Chromatin
remodeling
Histone 
modification
RNAi
Euchromatin Heterochromatin
 
Fig. 2. Epigenetic network. Cell epigenetic network consists of DNA methylation, histone 
methylations (pentagon), histone acetylation (triangle), chromatin (nucleosome) remodeling, 
and RNA interference (RNAi) induced by microRNAs and short interfering RNAs (siRNAs). 
Interaction between these epigenetic components results in transition of euchromatin to 
heterochromatin. The transcription is inactivated (silenced) permanently when the focal 
open chromatin becomes a closed heterochromatin configuration (Adapted from Wang MX 
and Shi HD: Basics of Molecular Biology, Genetic Engineering and Metabolic Engineering. 
In: Fu, PC, Latterich, M, and Panke, S (Eds): Systems Biology and Synthetic Biology, John 
Wiley & Sons, Inc., pp.36, 2009, with permission) 
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factors and therefore cannot be transcribed. Finally, non-coding RNAs play a role in gene 
expression by binding and degrading messenger RNA and inhibiting protein assembly 
(Chen J et al, 2010, Melo and Esteller, 2011). While each of these modifications plays an 
important role in gene expression, DNA methylation has been the most widely studied 
epigenetic modification that is associated with the development of acute leukemia and other 
types of cancer. 
DNA methylation occurs globally in the normal genome and is estimated to affect between 
70 and 80% of all CpG dinucleotides in human cells (Bird, 1980; Robertson & Jones, 2000). 
These dinucleotides are not uniformly distributed across the genome but occur in clusters 
such as large repetitive sequences or in CG-rich DNA stretches known as CpG islands 
(CGIs). Normally, the majority of the CpG dinucleotides which are found in intragenic 
regions, including repetitive sequences such as satellite sequences and centromeric repeats, 
contains methylated CpG dinucleotides;  while CGIs which are found preferentially in the 
promoter regions of genes typically contain unmethylated CpG dinucleotide (Craig & 
Bickmore, 1994). Some exceptions to this rule include those CGIs located on the inactive X 
chromosome in females (Goto & Monk,1998) and those associated with imprinted genes 
(genes for which only the paternally- or maternally-inherited allele is expressed) which are 
methylated in the normal state (Li et al., 1993; Razin & Cedar, 1994). 
In leukemia, the normal pattern of methylation gets reversed. Those regions of the genome 
that are normally methylated (and inactivated) such as repetitive sequences lose 
methylation and result in genomic instability. Those regions of the genome which are 
typically unmethylated such as the promoters of tumor suppressor genes become 
methylated and gene expression is lost. A typical gene comprises a promoter region, 
transcriptional start site (TSS), 5’ untranslated region (UTR), exons, introns and a 3’UTR. 
CGIs may encompass each of these genetic regions. Typically methylation present within 
the gene body (exons, introns) is associated with gene expression and methylation present in 
gene promoters, 5’UTRs and the first exon is associated with gene silencing. The majority of 
genome-wide methylation studies to date have focused on CGI at the promoter regions of 
genes via microarray methylation analysis. Recently, it has been suggested that not only are 
the CGI themselves important but that the flanking genomic regions termed CpG shores are 
more highly correlated with gene silencing (Irizarry et al., 2009). 
5. Emerging epigenetic technologies 
DNA methylation plays an important role in acute leukemia. This is evidenced by the 
growing number of studies that have recently been published describing methylation 
profiles for many types and subtypes of leukemia. A number of strategies have been used to 
examine DNA methylation and over time these methods have progressed from small-scale 
candidate gene analysis to the ability to construct whole-genome methylation profiles 
(Laird, 2010). These can broadly be divided into three classes: those that require bisulfite 
conversion, those that are affinity based and those that require the use of restriction 
enzymes. Restriction enzyme-based methods such as DMH (Huang et al., 1999) and MCA 
(Huang et al., 1999; Toyota & Issa, 2002) rely on methylation-sensitive enzymes and are 
limited by the fact that restriction sites are not present in all possible CpG rich regions of 
interest. In affinity based approaches such as methylated DNA immunoprecipitation 
(MeDIP) (Weber et al., 2005) and methylated CpG island recovery assay (MIRA) (Rauch & 
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Pfeifer, 2005), fragmented DNA is immunoprecipitated using a monoclonal antibody to 5-
methylcytosine or by methylated DNA binding proteins respectively. Methylated DNA is 
enriched in affinity based methods, however, these methods are limited by the sensitivity of 
the antibody or protein being used and are typically biased towards regions of the genome 
with a high density of methylation. Sodium bisulfite converts unmethylated cytosines to 
uracils in DNA strands. Once the conversion has taken place the sequence can be 
determined after PCR because the cytosines that were originally unmethylated will be 
converted to thymines and those that are methylated will remain cytosines. The net effect of 
the conversion process is that the complexity of the genome is reduced from 4 bases to only 
3 bases. Bias may be introduced due to incomplete bisulfite conversion, destruction of DNA 
strands and also by the efficiency of bisulfite PCR. After the samples are prepared, they can 
be hybridized to microarrays or used to make sequencing libraries for next generation 
sequencing. The recent development of high throughput technologies holds the promise of 
providing biological insight and new avenues for translational research and clinical 
applications. 
5.1 Arrays 
The extent of genome coverage is primarily determined by the resolution of the utilized 
microarray platform which has progressed rapidly from arrays that examine the DNA 
methylation present in select CGI to those that examine all CGIs and/or promoters and even 
to those that examine the entire genome (i.e. Agilent and Nimblegen). Microarray analysis is 
dependent upon the sample preparation used. Those that use restriction enzymes typically 
involve a co-hybridization of a test (i.e. leukemia) sample and a reference sample (i.e. bone-
marrow cells from a healthy donor). Differential methylation is determined by comparing 
the intensity of the test sample to the intensity of the reference sample at each locus 
represented on the array. If the DNA is prepared using an affinity method, the reference 
sample is usually an aliquot of the original sample DNA while the test sample is the 
immunoprecipitated portion derived from the original sample. Methylated sequences are 
detected by comparing the fluorescence signal for each probe corresponding to known 
genomic sequences for reference and the test samples. The loci that are enriched in the test 
sample are potential methylation candidates. There are also arrays that require DNA to be 
bisulfite converted (i.e. Illumina). These arrays are also known as SNP chips and methylated 
cytosines are identified by the presence of a cytosine at a particular locus as opposed to a 
thymine. These later arrays give site-specific methylation profiles whereas the 
oligonucleotide microarrays give region specific methylation profiles. 
5.2 Next Generation Sequencing (NGS) 
Next generation sequencing has revolutionized the ability to perform genomic research 
since it was introduced in 2007 (Metzker, 2010 for a review). More recently, this technology 
has been adapted to epigenomic research including DNA methylation analyses. NGS 
technologies can generate millions of sequencing reads in parallel and has led to a dramatic 
increase in the number of genomic and epigenomic sequences encompassing normal and 
diseased tissues. There are multiple sequencing platforms available and the choice of 
platform and methodology is dependent on the scientific application and the capacity for 
extensive bioinformatics analysis. 
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Whole genome bisulfite sequencing (WGBS) provides coverage at a single base pair 
resolution and is the most comprehensive NGS technology in DNA methylation analysis. 
WGBS provides unbiased coverage of the genome allowing for interrogation of whole 
regions of the genome that are often missed by other methodologies. This method requires 
the most extensive bioinformatics and is the most expensive because more sequences are 
required to cover the entire genome. Therefore, this option may not be suitable for 
laboratories without bioinformatics support or with a small budget. 
Reduced representation bisulfite sequencing (RRBS) is a less expensive alternative to WGBS. 
As the name of the method implies, the genome is reduced in size using an enzyme which 
enriches for regions of the genome that contain CpG dinucleotides. To be more specific, 
coverage includes approximately 12% of all CpG dinucleotides and 84% of all CpG islands 
in the human genome (Smith et al., 2009). In total, about 1% of the genome is covered which 
greatly reduces the cost of sequencing and the resources needed for alignments while 
providing data for those regions of the genome that are enriched for CpG dinucleotides. 
RRBS is an excellent alternative to WGBS with the caveat that important genomic regions 
that are not enriched for CpG dinucleotides are not assayed. As an example of the 
consequence of this limitation, it was recently published that much of the methylation 
present in colon cancer occurred in CGI shores and that this methylation was highly 
correlated with gene expression (Irizarry et al., 2009). RRBS covers less than 50% of the CGI 
shores so in this particular region of the genome, important data may be lost (Gu et al., 
2011). RRBS may become an optional platform for targeted DNA methylation analysis for 
clinical diagnostic purposes.  
Affinity sequencing utilizes either an antibody against 5-methylcytosine or proteins with 
methyl binding domains to immunoprecipate (or enrich for) methylated DNA. This method 
does not require bisulfite conversion and produces sequences for regions of the genome that 
are methylated. However, it does not provide data for the methylation status of individual 
CpG dinucleotides. Bioinformatics analysis requires genome alignment and must take into 
account the density of CpG dinucleotides in a given region because the efficiency of anti-5’ 
methylcytosine and methyl binding proteins is dependent on the number of methylated 
cytosines in a given region (Weber et al., 2005).  
6. DNA methylation in acute leukemia 
DNA methylation is an important epigenetic mechanism to control gene expression. In many 
cases, tumor suppressor genes (TSGs) are inactivated by somatic mutations (point mutations 
or deletions) as the “first hit”, DNA methylation silences the gene expression of other allele as 
the “second hit”, or in a reversed sequence. In this regards, aberrant DNA methylation plays a 
crucial role in leukemogenesis (Herman & Baylin, 2003; Galm et al., 2006). Using various 
technologies described above, many aberrant DNA methylation loci have been identified in 
both ALL and AML  
6.1 DNA methylation in ALL  
Genomic DNA methylation profile in a given cell is defined as methylome. There are 
numerous recurrent chromosomal and genetic abnormalities in ALL. However, these 
abnormalities are neither sufficient nor necessary in the development of ALL. Therefore it is 
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likely that epigenetic modifications also contribute to the leukemogenesis in ALL. 
Numerous studies have been published that have focused on a single candidate gene or 
groups of genes involved in important cellular processes such as cell signaling pathways, 
apoptosis, regulation of transcription and cell cycle control in pediatric ALL (Agirre et al., 
2006; Canalli et al., 2005; Cheng et al., 2006; Corn et al., 1999; Garcia-Manero et al., 2003; 
Gutierrez et al., 2003; Iravani et al., 1997; Paixao et al., 2006; Roman-Gomez et al., 2002; 
Roman-Gomez et al., 2004; Roman-Gomez et al., 2006, 2007; Sahu & Das, 2005; Scholz et al., 
2005; Stam et al., 2006; Tsellou et al., 2005; Yang et al., 2006; Zheng et al., 2004), and adult 
ALL (Batova et al., 1997; Chim et al., 2001; Garcia-Manero et al., 2002a; Garcia-Manero et al., 
2002b; Hutter et al., 2011; Jimenez-Velasco et al., 2005; Martin et al., 2008; Roman et al., 2001; 
Roman-Gomez et al., 2004; Scott et al., 2004; Shteper et al., 2001; Taniguchi et al., 2008; Yang 
et al., 2006). A search of PubMeth (www.pubmeth.org) provides a list of 46 methylated 
genes that have been associated with acute lymphoblastic leukemia including ABCB1, ABL1, 
ADAMTS1, ADAMTS5, AHR, APAF1, BNIP3, CDH1, CDH13, CDKN1A, CDKN1C, CDKN2A, 
CDKN2B, CHFR, DAPK1, DIABLO, DKK3, ESR1, EXT1, FHIT, HCK, KLK10, LATS1, LATS2, 
LMNA, MGMT, MME, MYOD1, NNAT, NR0B2, PARK2, PGR, PPP1R13B, PTEN, PYCARD, 
RARB, SFRP1, SFRP2, SFRP4, SFRP5, SYK, THBS1, THBS2, TP73, WIF1 and WRN.  
Recent studies have increased our knowledge of aberrantly methylated loci in ALL by 
utilizing genome-wide technologies to construct genome-scale methylomes. These studies 
have shown that methylation profiles can be used in diagnosis (Davidsson et al., 2009; 
Dunwell et al., 2010; Milani et al., 2010; Stumpel et al., 2009; Taylor et al., 2007a; Taylor et al., 
2007b; Vilas-Zornoza et al., 2011), prognosis (Davidsson et al., 2009; Hogan et al., 2011; 
Kuang et al., 2008; Milani et al., 2010), and in the treatment (Hogan et al., 2011; Vilas-
Zornoza et al., 2011) of individuals with ALL.  
As an example of the breadth and depth provided by using  genome-scale technologies, 
Davidsson and colleagues used bacterial artificial chromosome arrays and genome-wide 
methylation arrays in two of the most common subtypes of pediatric ALL, t(12;21)(p13;q22) 
and high hyperdiploidy (Davidsson et al., 2009). The methylation microarray used covers all 
of the UCSC-annotated CGI and promoter regions of all RefSeq genes and contains a total of 
385,000 probes. A total of 8,662 genes were identified with significant methylation present 
within the promoter and the 10 individuals with hyperdiploid ALL had approximately 
twice as many hypermethylated genes as the 10 individuals with the t(12;21) abnormality. 
Of particular importance is that none of the 30 genes with the highest methylation peaks in 
the ALL patients have previously been shown to be methylated in ALL or any other 
neoplasia. An additional study by Hogan and colleagues (Hogan et al., 2011) used the 
Infinium Human Methylation27 BeadChip to create methylation profiles for paired 
diagnostic/relapse samples from 33 pediatric ALL patients. This study identified over 900 
genes that were preferentially methylated in relapse samples when compared to samples at 
diagnosis. Further combinatorial expression and copy number variation analysis identified 
important biological pathways such as the WNT/beta-catenin pathway and the MAPK 
pathway which may be implicated in the relapse of pediatric ALL. 
6.2 DNA methylation in AML 
Like in the case of ALL, numerous studies have been published using single-gene based 
methods such as methylation-specific PCR (MSP), combined bisulfite restriction analysis 
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(COBRA) or array to identify a single or a group of genes with abnormal DNA methylations 
in AML. The examples include CDH1, ESR1, IGSF4, FHIT, p15INK4B, p21CIP1/WAF1, MEG3, 
SNRPN, p73, SOCS1, CALC1, HIC-1, CTNNA1, CEBPA, MLH1, MGMT, CNAML, HOXA1, 
MYOD, KRT13, NR2F2, PITX2, RBP1, CEBPA, BAHCC1, EVI1, and DAPK genes (Ekmekci et 
al., 2004; Agrawal et al., 2007; Desmond et al., 2007; Glasow et al., 2008; Rosu-Myles & Wolff, 
2008; Melnick, 2010;  Oki & Issa, 2010; Lugthart et al., 2011; Lin et al., 2011). Often 
hypermethylation in these gene CpG-island-promoters results in transcriptional silencing 
and loss of the function in important biological pathways (Calvanese et al, 2011).  
High throughput technologies such as mass spectrometry, microarray and next generation 
sequencing (NGS) have been used to study altered DNA methylation at the genome-wide 
scale. Bullinger and colleagues used a combination of base-specific cleavage biochemistry 
and mass spectrometry (MALDI-TOF-MS) to quantify DNA methylation in 92 selected 
genomic regions of 256 AML patient samples (Bullinger et al., 2010). Distinct DNA 
methylation patterns were identified in abnormal cytogenetic subgroups and the DNA 
methylation levels (CpG units) could provide independent prognostic information. Alvarez 
and colleagues used a bead array-based methylation assay to examine the methylation 
status of 1,505 CpG-sites from 807 genes on 116 de novo AML patients (Alvarez et al., 2010). 
They confirmed that the DNA methylation signatures were associated with the specific 
cytogenetic status. In addition, aberrant DNA methylation of the promoter of DBC1 could 
predict the disease-free and overall survival time in normal karyotype cases. Interestingly, 
the aberrant DNA methylation pattern could be induced by genetic transduction of MLL 
rearrangement fusion genes in normal human hematopoietic stem/progenitor cells (HSPC), 
but cannot be induced by AML1/ETO or CBFB/MYH11 fusion gene. This is the direct 
evidence of interaction between genetic and epigenetic alteration in AML. Using the same 
platform, Wilop and colleagues found a gain of overall methylation in 32 AML patient 
samples (Wilop et al., 2011). The methylation pattern was maintained at relapse with 
increased density and extended to addition genes, consistent with the previous studies 
(Agrawal et al., 2007; Kroeger et al., 2008). These observations provided a strong scientific 
basis for DNA methylation to be used as a biomarker for diagnosis, minimal residual 
disease detection and clinical follow-up in AML patients.  
A more comprehensive study was conducted by Figueroa and colleagues using HpaII tiny 
fragment enrichment by ligation-mediated PCR (HELP), linked with a microarray platform 
measuring the methylation abundance of 50,000 cytosines distributed among 14,000 gene 
promoters in 344 AML patient samples (Figueroa et al., 2010). Based on the DNA methylation 
signatures, these patients could be classified into 16 epigenetically unique subtypes. Although 
the DNA methylation patters were different among subtypes, none of the AML subtypes were 
similar to any of the stages of normal myeloid maturation indicating a distinct difference 
between leukemia and normal myeloid cell methylomes. Furthermore, they found a set of 45 
genes to be aberrantly methylated common in all AML cases, but not in normal myeloid cells. 
Patients with a CEPBA signature have markedly poor clinical outcomes. Functionally, the 
hypermethylated genes were down-regulated and associated with biologically relevant 
pathways in leukemogenesis. These genes include zinc finger transcription factors, 
components in retinoic acid, STAT, p53 signal pathways, DNA-damage repair, immune 
response and tumor suppressors (Sternberg et al, 2004). It is anticipated that a complete AML 
methylome with single base pair resolution by next generation sequencing such as whole 
genome bisulfite sequencing (WGBS) will be published soon. 
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7. Interaction between genome and epigenome in leukemia 
Data from cytogenetic karyotyping, conventional sequencing, microarray and whole 
genome sequencing indicates that there are extensive and distinct genetic and epigenetic 
alterations in acute leukemia genomes. Recent studies showed that genetic and epigenetic 
alterations are not independent events. Specific DNA methylation patterns are identified in 
specific cytogenetic subgroups of ALL (Davidsson et al., 2009) and AML (Figueroa et al., 
2010). Chromosomal translocations result in fusion oncoproteins that can recruit 
components for DNA methylation, histone deacetylation and transcriptional repressor 
complexes (Croce LD, 2005; Chen et al., 2010). In contrast, DNA hypomethylation may lead 
to abnormal microRNA expression and chromosomal instability that in turn may result in 
chromosomal translocations (Eden et al. 2003; Calvanese et al, 2010; Popp & Bohlander et al., 
2010; Toyota et al. 2010; Melo and Esteller, 2011).  
AML with t(8;21)(q22;q22) translocation results in the fusion genes of RUNX1-RUNX1T (or 
AML1- ETO). The oncoprotein represses the transcription of wild-type AML1 target genes 
by recruiting co-repressor complexes (Ferrara & Del Vecchio, 2002). AML1 (also known as 
RUNX1 or CBFA) is a transcription factor containing the DNA binding domain of the ǂ-
subunit of core binding factor (CBF). Another subtype of AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22) results in CBFB-MYH11 fusion gene that contains a ǃ subunit of CBF. 
Together, ǂ-subunit and ǃ subunit forms a heterodimeric core binding transcription factor 
and plays an important role in normal hematopoiesis and myeloid differentiation (Link et 
al., 2010). However, fusion forms of these truncated subunits lost the ability to form core 
binding factor and no longer induce myeloid differentiation (Paschka, 2008). Even more, the 
fusion proteins actively repress the transcription of normal AML1 target genes by either 
recruiting histone deacetylase (HDAC) or DNA methyltransferase 1 (DNMT1) or by 
cooperating nuclear receptor co-repressor 1 (NCOR1), NCOR2 and sIN3A15 to form a 
repressor complex (Liu et al., 2005). As a result, normal myeloid differentiation mediated by 
CBF is disrupted and hematopoietic stem cells (HSCs) and myeloid progenitor cells cannot 
achieve the next mature stages, and result in accumulation of leukemia blasts in bone 
marrow and blood. Since AML with t(8;21) and inv(16) or t(16;16) are involved in a common 
pathway at the molecular level and show specific clinical features, these two genetic 
subtypes are called  core binding factor leukemia (Ferrara & Del Vecchio, 2002). This 
leukemia responds well to high doses of cytorabine (HiDAC) and has a better prognosis 
(Dombret et al., 2009; Solis, 2011).  
Acute promyelocytic leukemia (APL) is another example in which blockage of myeloid 
differentiation by the fusion oncoproteins is mediated by an interaction between genetic and 
epigenetic mechanisms. All patients with APL have the t(15;17) translocation or one of its 
variants t(11;17), t(5;17) (Warrell et al., 1993). Translocation t(15;17) results in a fusion 
protein PML-RARA typically comprised of variable portions of PML protein and all but the 
first 30 amino acids of retinoic acid receptor-ǂ (RARA). Wild-type RARA protein is a 
transcriptional activator crucial for normal hematopoiesis and myeloid differentiation. 
Many RARA target genes including specific transcription factors such as PU.1 (SPI1) and 
C/EBP┚ (CEBPB) have been identified to have RARA biding sites. The fusion protein PML-
RARA functions as a transcriptional repressor, but not an activator, by binding to promoter 
region of RARA target genes and recruiting proteins including HDAC, NCOR1 and NCOR2 
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(N-CoR) complex, DNMT1, DNMT3A, repressive histone methyltransferases and polycomb 
group proteins (Licht et al., 2006). DNA methyltransferases (DNMT1 and DNMT3A) induce 
DNA methylation. Histone deacetylase (HDAC) removes acetyl group from histones. Together 
with other repressive proteins, the focal chromatin structure at the promoter regions of target 
genes are converted to a closed configuration and the transcription initiation is abolished. 
Promyelocytes of APL lack key transcription factors for further maturation. Accumulation of 
abnormal promyelocytes in bone marrow is a diagnostic feature of APL. A high dose of all-
trans-retinoic acid (ATRA) relieves this repression by allowing the release of the N-CoR 
complex and the recruitment of a co-activator complex and it has become the cornerstone in 
treatment of APL by molecular targeting (Wang & Chen, 2008).  
8. Molecular mechanisms of leukemogenesis 
Among more than 100 types of cancer with different tissue origins, acute leukemia is a 
unique form that is originated from hematopoietic stem cells (HSC) or hematopoietic 
progenitor cells in bone marrow. In order to acquire a malignant phenotype, leukemic cells 
must have all the malignant  biological properties including self-sufficiency in growth 
signals, insensitivity to growth-inhibitory  signals, altered cellular metabolism, evasion of 
programmed cell death (apoptosis) and immunological destruction, limitless replicative 
proliferation and tissue invasion and metastasis (Hanahan & Weinberg, 2000; 2011). At the 
molecular level, the phenotype of leukemic cells represents a global change of gene 
expression due to irreversible genetic and epigenetic alterations. These changes affect 
biological pathways of cell differentiation, cell cycle regulation, tumor suppression, drug 
responsiveness, and apoptosis. Identification of the molecular signature of leukemia as well 
as the genetic background of the host individual will provide a unique biological road map 
for each patient that will become the foundation for personalized therapy in the future 
(Godley et al., 2011). 
The etiology of acute leukemia is not completely clear. Some environmental risk factors for 
ALL including parental occupation, parental tobacco or alcohol use, prenatal vitamin use, 
diet, exposure to pesticides or solvents, infectious pathogens and exposure to ionizing 
radiation or the highest levels of residential power-frequency magnetic fields have been 
reported (Belson et al., 2007;  Milne et al, 2010; Bailey et al., 2011). Environmental risk factors 
for AML include exposure to ionizing radiation and benzene (Bowen, 2006; Smith et al., 
2011). The cytotoxic chemotherapy (alkylating agents and topoisomerase-II inhibitors) 
and/or radiotherapy for other solid tumors and pre-leukemic conditions myelodysplastic 
syndromes in the elderly are proven risk factors for AML (Löwenberg  et al., 1999; Garcia-
Manero et al., 2011).  
ALL occurs exclusively in childhood although adult ALL exists. Screening of neonatal cord-
blood samples has revealed several specific leukemic chromosomal translocations. One 
particular clone with the TEL-AML1 fusion gene derived from chromosomal translocation 
t(12;21)(p13;q22) is found in 1% of newborn babies. The prevalence of B-ALL with this 
fusion gene is 100 times higher than those who do not have the fusion gene (Cobaleda et al., 
2009; Lausten-Thomsen et al., 2011). Similarly, some leukemic translocations such as 
t(8;21)(q22;q22) resulting in AML1-ETO fusion gene can be detected in neonatal blood 
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samples from the teenagers diagnosed with AML (Mori et al., 2002). In addition, ALL and 
AML occurs in approximately 10% of identical twins with these or other karyotypes (Mori et 
al., 2002; Greaves et al., 2003). These observations support the hypothesis that these specific 
genetic alterations at the fetal stage increases the frequency of ALL and AML, but additional 
postnatal events,  either genetic or epigenetic, are required for full leukemic transformation 
(Greaves & Wiemels, 2003; McHale et al., 2004; Wiemels et al., 2009).  
Recent studies suggest that the original leukemic clone is most likely raised from 
hematopoietic stem cells (HSC) or lineage committed precursor cells (Clarke et al. 1987; 
Lapidot et al., 1994; Cox et al., 2004, 2007; Jamieson et al., 2004). Under the influence of 
genetic and the environmental risk factors described above, normal HSC or precursor cells 
undergo malignant transformation and become leukemia stem cells (LSCs) (Passegué et al, 
2003). LSCs have the distinct properties with partial normal HSC and partial leukemia cell 
features. These cells are characterized by self-renewal, over proliferation and the capacity to 
develop an entire leukemic blast population (Huntly & Gilliland, 2005; Becker & Jordan, 
2010). Identification of LSCs by specific biomarkers and development of specific agents to 
target LSCs has significant clinical implication since eradication of LSCs will prevent the 
relapse and cure the leukemia (Jan et al., 2011). 
At the molecular level, based on the facts that chromosomal translocations and point 
mutations can be found in the majority of AML patients, Kelly and colleagues suggested a 
two-hit model that AML leukemogenesis driven by two types of gene mutations (Kelly et 
al., 2002). The class 1 mutations result in constitutive activation of cell-surface receptors, 
such as receptor tyrosine kinases, FLT3 and KIT. Through various downstream signaling 
pathways, constitutive activation confers proliferation and survival advantage leading to 
clonal expansion of the affected hematopoietic stem cell or progenitors. The class 2 
mutations, exemplified by formation of fusion genes from the t(8;21) or inv(16) 
chromosomal translocations or overexpression of HOX genes, block myeloid differentiation. 
Either class 1 or class 2 lesions alone does not cause leukemia in mouse models (Downing, 
2003). AML develops only when both classes of lesions are present. 
This model, however, provides a less cogent explanation for AML derived from 
myelodysplastic syndrome and therapy-related AML (t-AML) in elderly. These AML are 
frequently associated with chromosomal deletion or addition (Godley & Larson, 2008). 
Furthermore, this model also does not fully explain the AML containing normal karyotype 
with multiple point mutations in FLIT3, NPM1, and CEBPA genes (Foran, 2010). The class 1 
mutations in ALL have not fully established. Epigenetic factors, especially DNA 
hypermethylation that can inactivate various putative tumor suppressor genes, DNA-repair, 
cell cycle, apoptosis related genes appear to play important roles in leukemogenesis (Issa et 
al., 1997; Esteller, 2008; Kulis & Esteller, 2010; Deaton & Bird, 2011). An integrated model 
combining genetic and epigenetic factors at the individual, cellular and molecular levels for 
acute leukemia is proposed (Figure 3).  
9. Clinical applications 
Genetic and epigenetic studies from basic science have been applied to many aspects in the 
clinical management of acute leukemia patients. The current WHO classification of tumors 
of hematopoietic and lymphoid tissues has included an increasing number of 
clinicopathologic entities defined by chromosomal abnormalities as well as gene mutations.  
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Fig. 3. A new model of leukemogenesis integrated genetic and epigenetic mechanisms and 
their clinical implications. Although the inherited factors in leukemogenesis of acute 
leukemia is not apparent, the genetic alterations including chromosomal translocations and 
numerical changes such as trisomy 21 have been found at prenatal stage. The changes may 
be related to maternal factors such as carcinogens exposure, nutrients (including folate) and 
aging in pregnancy. The incidence of acute leukemia is dramatically increased (~100 times 
higher), but not all children will have the leukemia when carrying the specific chromosomal 
abnormalities at the prenatal stage. It indicates the second hit, either genetic mutations or 
epigenetic alterations, is required for a full leukemic transformation. With an interaction 
between genetic and epigenetic networks, the gene expression profile is globally changed in 
hematopoietic stem cell s or precursors. Corresponding functional changes including cell 
signalings and cell cycle control result in a malignant leukemia phenotype. These leukemia 
cells escape from immune surveillance and accumulate in bone marrow and blood, thus 
acute leukemia is developed. Clinically, genetic abnormalities have been used as biomarker 
for disease classification and diagnosis, while aberrant epigenetic alterations have become 
therapeutic targets. Note: HSC: hematopoietic stem cell; TSG: tumor suppressor gene; 
DNMTI; HDACI; RNAi; Epigenetic network: DNA methylation, histone modifications and 
microRNA. siRNAs. +: increase; -: decrease; x: disruption. 
These subtypes of AML or ALL often have a distinct morphology, immunophenotype and 
clinical course. Some of these patients with specific genetic or epigenetic alterations may 
respond to specific chemotherapeutic reagents or epigenetic modifiers. Mutation status of 
NPM1, CEBPA and FLT3 genes has been used in risk assessment, prognostic evaluation and 
guidance of therapy (Foran, 2010). Detection of specific fusion RNA levels using 
quantitative RT-PCR molecular tests in patient blood has been used routinely for 
therapeutic monitoring and minimal residual disease detection (Gulley et al., 2010). 
Because of the genetic heterogeneity and the limited number of meaningful genetic 
biomarkers identified in acute leukemia, the use of aberrant epigenetic alterations, 
especially DNA methylation and microRNA as biomarkers, is being studied at the single 
gene as well as genome-wide level. Agrawal and colleagues reported that the methylation 
of ER┙ and p15INK4B genes occurred frequently and specifically in acute leukemia but not 
in healthy controls or in nonmalignant hematologic diseases (Agrawal et al., 2007). 
Aberrant DNA methylation of these two genes was detectable in >20% of leukemia 
patients during clinical remission. The presence of detectable methylation was correlated 
to minimal residual disease (MRD) and associated with subsequent relapse (Agrawal et 
al., 2007). Wang and colleagues demonstrated that the aberrant DNA methylation of DLC-
1, PCDHGA12 and RPIB9 genes can be identified in over 80% of ALL patients (Wang et 
al., 2010). Using a single gene DLC-1, we could trace clinical B-ALL cases up to 10 years 
retrospectively and the DLC-1 methylation is correlated with patient clinical status. 
Importantly, these specific DNA methylation loci are retained in leukemia cells and can be 
detected in relapse. Compared with primary leukemia at diagnosis, relapsed leukemia 
maintains the original methylation loci, yet extents methylation in addition genes 
(Kroeger et al., 2008; Figueroa et al., 2010). These studies indicated that the DNA 
methylation is a biologically stable marker that can be used for MRD detection and 
patient follow up in acute leukemia. 
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In terms of therapy, there are two groups of epigenetic agents currently in clinical use, DNA 
methyltransferase inhibitor (DNMTI) and histone deacetylase inhibitor (HDACI) (Peters & 
Schwaller, 2011). The prototypic nucleoside analogue DNMT inhibitors include 5-
azacytidine (5-Aza or azacitidine) and 5-aza-2′deoxycytidine (decitabine). They exert a 
demethylating effect by incorporating into DNA (5-Aza is also incorporated into RNA) and 
form a covalent complex with the DNMT enzymes. The enzymes are trapped and 
eventually degraded and the newly synthesized DNA strand will not be methylated 
(Schoofs & Müller-Tidow, 2011). These two agents are active in a broad range of myeloid 
neoplasms including AML and myelodysplastic syndrome (MDS). Because of its excellent 
efficacy (~50% response rate) in clinical trials, both agents have been approved by the US 
FDA for the treatment of MDS (Silverman & Mufti, 2005). The use of these reagents in 
treatment of AML has been actively investigated and showed promising utility especially in 
elderly patients (Musolino, 2010). The second group of epigenetic therapeutic agents is 
histone deacetylase inhibitor (HDACI). This group consists of heterogenic compounds that 
may reactivate the genes that have been turned off by histone deacetylation. Particularly, 
HDACI has demonstrated some efficacy in treat of core binding factor (CBF) leukemia. 
Clinical trials have been conducted using HDACI alone or in combination with DNMTI in 
CBF and other subtypes of leukemia patients (Quintás-Cardama et al., 2011). 
10. Conclusion 
Acute leukemia (ALL and AML), like all other cancer types, is a genetic disease. DNA 
sequence examination in the specific loci as well as at the genome-wide level has 
confirmed this original hypothesis. Epigenetic alterations including DNA methylation, 
histone modifications and microRNA play a functional role in leukemogenesis. 
Interaction between genetic and epigenetic elements changes the global landscape of gene 
expression, protein synthesis and metabolism in hematopoietic stem cells and/or 
committed precursor cells which results in leukemic transformation. Systemic study at the 
genome level in DNA sequence and DNA methylation, gene and microRNA expression 
profile, proteome and metabolism not only provides the insight for understanding 
leukemogenesis, but also identifies biomarkers for leukemia stem cell, leukemia 
classification, diagnosis, risk assessment, therapy selection, response prediction, 
prognosis, minimal residual disease detection and other aspects of clinical decision-
making and applications. Toward this end, current advanced high throughput 
technologies including next generation sequencing, microarray, proteomics, targeted 
molecular testing and bioinformatics have provided powerful tools. Well-designed 
clinical trials will make a clinical connection with new scientific discoveries in leukemia 
genome and epigenome. Assembly and synthesis of the massive amounts of new 
information by systems biology will generate a high resolution picture of leukemogenesis 
of acute leukemia. With combined efforts from bench and bedside, the ultimate goal is to 
eradicate all leukemic blasts including leukemic stem cells in the patients by less toxic 
reagents to completely cure leukemia in the future. 
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